Metabolic syndrome in Cushing's syndrome

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 96-101

  Chanson, Philippe ^a,b,c   Salenave, Sylvie ^a  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cardiovascular risk; Cushing's syndrome; Diabetes mellitus; Glucocorticoids; Growth hormone deficiency; Metabolic syndrome

Indexed keywords

GLUCOCORTICOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONFERENCE PAPER; CORTICOSTEROID METABOLISM; CUSHING SYNDROME; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

CARDIOVASCULAR DISEASES; CUSHING SYNDROME; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; RISK FACTORS;

EID: 77956511020     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314272     Document Type: Conference Paper

References (44)

1. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB: Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:2906-2912.
2. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classifi-cation of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285, 2486-2497.
4. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062. (Pubitemid 41338752)
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:164 0-1645.
7. Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing's syndrome. Lancet 2006; 367:1605-1617.
8. Faggiano A, Pivonello R, Spiezia S, De Mar-tino MC, Filippella M, Di Somma C, Lom-bardi G, Colao A: Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 2527-2533.
9. Pivonello R, Faggiano A, Lombardi G, Colao A: The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin Nort h A m 2005; 34: 327-339, viii.
10. Lee CM, Huxley RR, Wildman RP, Woodward M: Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 2008; 61:646-653.
11. Wajchenberg BL, Bosco A, Marone MM, Levin S, Rocha M, Lerario AC, Nery M, Goldman J, Liberman B: Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocrinol Metab 1995; 80: 2791-2794.
12. Garrapa GG, Pantanetti P, Arnaldi G, Man-tero F, Faloia E: Body composition and meta-bolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab 2001; 86: 5301-5306.
13. Mayo-Smith W, Hayes CW, Biller BM, Klibanski A, Rosenthal H, Rosenthal DI: Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 1989; 170:515-518.
14. Burt MG, Gibney J, Ho KK: Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006; 64: 436-443.
15. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E: Effects of glucocor-ticoids on energy metabolism and food intake in humans. Am J Physiol 1996; 271:E317-E325.
16. Ahdjoudj S, Lasmoles F, Oyajobi BO, Lomri A, Delannoy P, Marie PJ: Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotential clonal human marrow stromal F/STRO-1(+) cells. J Cell Biochem 2001; 81: 23-38.
17. Fried SK, Russell CD, Grauso NL, Brolin RE: Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 1993; 92:2191-2198.
18. Sakayama K, Masuno H, Kidani T, Matsuda Y, Yamamoto H, Okuda H: Synthesis of active high mannose-type lipoprotein lipase in human adipose tissues. Atherosclerosis 2001; 155: 29-35.
19. Taskinen MR, Nikkila EA, Pelkonen R, Sane T: Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab 1983; 57: 619-626.
20. Christ-Crain M, Kola B, Lolli F, Fekete C, Se-boek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J, Kunos G, Muller B, Pralong F, Aubert G, Arnaldi G, Giacchet-ti G, Boscaro M, Grossman AB, Korbonits M: AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008; 22:1672-1683.
21. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
22. Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M: Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008; 93: 4969-4973.
23. Andrews RC, Walker BR: Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96: 513-523.
24. Qi D, Rodrigues B: Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 2007; 292:E654-E667.
25. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP: Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009; 94: 2692-2701.
26. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112:83-90.
27. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
28. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR: Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11beta-hydroxysteroid dehydro-genase type 1-deficient mice. Diabetes 2004; 53: 931-938.
29. Cooper MS, Stewart PM: 11Beta-hydroxys-teroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009; 94: 4645-4654.
30. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84:2664-2672.
31. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jor-gensen J, Kosteljanetz M, Kristensen L, Lau-rberg P, Schmidt K, Weeke J: Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86:117-123.
32. Hammer GD, Tyrrell JB, Lamborn KR, Ap-plebury CB, Hannegan ET, Bell S, Rahl R, Lu A, Wilson CB: Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 2004; 89:6348-6357.
33. Dekkers OM, Biermasz NR, Pereira AM, Ro-elfsema F, Van Aken MO, Voormolen JH, Romijn JA: Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007; 92:976-981.
34. Etxabe J, Vazquez JA: Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479-484.
35. Pikkarainen L, Sane T, Reunanen A: The survival and well-being of patients treated for Cushing's syndrome. J Intern Med 1999; 245: 463-468.
36. Swearingen B, Biller BM, Barker FG 2nd, Katznelson L, Grinspoon S, Klibanski A, Zervas NT: Long-term mortality after trans-sphenoidal surgery for Cushing disease. Ann Intern Med 1999; 130: 821-824.
37. Barahona MJ, Sucunza N, Resmini E, Fernandez-Real JM, Ricart W, Moreno-Na-varrete JM, Puig T, Farrerons J, Webb SM: Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009; 94: 3365-3371.
38. Hughes NR, Lissett CA, Shalet SM: Growth hormone status following treatment for Cushing's syndrome. Clin Endocrinol (Oxf) 1999; 51: 61-66.
39. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF: Long-term follow-up results of transsphenoidal surgery for Cush-ing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 2002; 56: 541-551.
40. Pecori Giraldi F, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sac-co E, Scacchi M, Pontecorvi A, Cavagnini F: Significant GH deficiency after long-term cure by surgery in adult patients with Cush-ing's disease. Eur J Endocrinol 2007; 156: 233-239.
41. Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Stahl E, Monson J P, Westberg B, Wilton P, Wuster C: Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease. Eur J Endocrinol 2002; 146: 67-74.
42. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P: Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-defi-cient patients before and after GH replacement. J Clin Endocrinol Metab 2010; 95: 74-81.
43. Van Der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA, Pereira AM: The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 2007; 156:455-462.
44. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW: Metabolic, cardiovascular, and cerebrovas-cular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 2010; 95:630-638.